OncoTEX Email Format
Biotechnology ResearchTexas, United States51-200 Employees
OncoTEX is developing TEX Core, a world-first oncology drug platform designed to create innovative therapies capable of overcoming multiple limitations often associated with current cancer therapeutics, including the predominant platinum-based resistance. OxaliTEX is the first clinical candidate developed from the TEX Core platform for the treatment of platinum-resistant ovarian cancer. TEX Core is designed to target tumor cells by overcoming challenges associated with the current platinum-based standards-of-care (SOC).